BioLine RX Ltd (BLRX) - Net Assets

Latest as of September 2025: ILA19.53 Million ILA ≈ $52.37K USD

Based on the latest financial reports, BioLine RX Ltd (BLRX) has net assets worth ILA19.53 Million ILA (≈ $52.37K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA39.80 Million ≈ $106.71K USD) and total liabilities (ILA20.27 Million ≈ $54.35K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BLRX financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	ILA19.53 Million
% of Total Assets	49.07%
Annual Growth Rate	0.28%
5-Year Change	-38.9%
10-Year Change	-71.73%
Growth Volatility	79.43

BioLine RX Ltd - Net Assets Trend (2005–2024)

This chart illustrates how BioLine RX Ltd's net assets have evolved over time, based on quarterly financial data. Also explore BLRX total assets for the complete picture of this company's asset base.

Annual Net Assets for BioLine RX Ltd (2005–2024)

The table below shows the annual net assets of BioLine RX Ltd from 2005 to 2024. For live valuation and market cap data, see BLRX stock market capitalisation.

Year	Net Assets	Change
2024-12-31	ILA13.46 Million ≈ $36.09K	+1.80%
2023-12-31	ILA13.22 Million ≈ $35.45K	-73.99%
2022-12-31	ILA50.84 Million ≈ $136.30K	-25.33%
2021-12-31	ILA68.09 Million ≈ $182.54K	+209.06%
2020-12-31	ILA22.03 Million ≈ $59.06K	-34.00%
2019-12-31	ILA33.38 Million ≈ $89.49K	-19.22%
2018-12-31	ILA41.32 Million ≈ $110.78K	-21.86%
2017-12-31	ILA52.88 Million ≈ $141.77K	+50.97%
2016-12-31	ILA35.03 Million ≈ $93.91K	-26.43%
2015-12-31	ILA47.61 Million ≈ $127.64K	+49.88%
2014-12-31	ILA31.77 Million ≈ $85.16K	+171.90%
2013-12-31	ILA11.68 Million ≈ $31.32K	-21.96%
2012-12-31	ILA14.97 Million ≈ $40.14K	-33.56%
2011-12-31	ILA22.53 Million ≈ $60.41K	-82.92%
2010-12-31	ILA131.96 Million ≈ $353.78K	+11.89%
2009-12-31	ILA117.94 Million ≈ $316.18K	+50.46%
2008-12-31	ILA78.39 Million ≈ $210.15K	-57.23%
2007-12-31	ILA183.25 Million ≈ $491.29K	+14819.12%
2006-12-31	ILA-1.25 Million ≈ $-3.34K	-109.75%
2005-12-31	ILA12.77 Million ≈ $34.22K	--

Equity Component Analysis

This analysis shows how different components contribute to BioLine RX Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 39982700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	ILA38.10 Million	283.02%
Other Comprehensive Income	ILA16.13 Million	119.84%
Other Components	ILA359.06 Million	2667.41%
Total Equity	ILA13.46 Million	100.00%

BioLine RX Ltd Competitors by Market Cap

The table below lists competitors of BioLine RX Ltd ranked by their market capitalization.

Company	Market Cap
Wong Engineering Corporation Bhd KLSE:7050	$9.10 Million
Transocean Holdings Bhd KLSE:7218	$9.10 Million
Paratech Company Limited KQ:033540	$9.10 Million
Burford Capital Limited LSE:BUR	$9.10 Million
PHOENIX NEW MED.ADR 1/48 F:1PX	$9.09 Million
Robin Energy Ltd. NASDAQ:RBNE	$9.09 Million
Fountain BR:FOU	$9.09 Million
Magna Polonia SA WAR:06N	$9.08 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BioLine RX Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 13,223,000 to 13,461,000, a change of 238,000 (1.8%).
Net loss of 9,221,000 reduced equity.
New share issuances of 16,357,000 increased equity.
Other comprehensive income decreased equity by 861,000.
Other factors decreased equity by 6,037,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	ILA-9.22 Million	-68.5%
Share Issuances	ILA16.36 Million	+121.51%
Other Comprehensive Income	ILA-861.00K	-6.4%
Other Changes	ILA-6.04 Million	-44.85%
Total Change	ILA-	1.80%

Book Value vs Market Value Analysis

This analysis compares BioLine RX Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 115.71x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.12x to 115.71x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-12-31	ILA10.60	ILA1.30	x
2011-12-31	ILA1.82	ILA1.30	x
2012-12-31	ILA0.88	ILA1.30	x
2013-12-31	ILA0.52	ILA1.30	x
2014-12-31	ILA0.98	ILA1.30	x
2015-12-31	ILA0.93	ILA1.30	x
2016-12-31	ILA0.62	ILA1.30	x
2017-12-31	ILA0.59	ILA1.30	x
2018-12-31	ILA0.38	ILA1.30	x
2019-12-31	ILA0.23	ILA1.30	x
2020-12-31	ILA0.09	ILA1.30	x
2021-12-31	ILA0.10	ILA1.30	x
2022-12-31	ILA0.07	ILA1.30	x
2023-12-31	ILA0.01	ILA1.30	x
2024-12-31	ILA0.01	ILA1.30	x

Capital Efficiency Dashboard

This dashboard shows how efficiently BioLine RX Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -68.50%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -31.86%
• Asset Turnover: 0.74x
• Equity Multiplier: 2.89x
Recent ROE (-68.50%) is above the historical average (-92.21%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	1.59%	6.57%	0.21x	1.17x	ILA-11.10 Million
2011	-58.52%	0.00%	0.00x	1.30x	ILA-15.44 Million
2012	-136.37%	0.00%	0.00x	1.62x	ILA-21.91 Million
2013	-151.01%	0.00%	0.00x	1.71x	ILA-18.81 Million
2014	-32.03%	0.00%	0.00x	1.14x	ILA-13.35 Million
2015	-30.25%	0.00%	0.00x	1.08x	ILA-19.16 Million
2016	-45.23%	0.00%	0.00x	1.11x	ILA-19.34 Million
2017	-46.05%	0.00%	0.00x	1.15x	ILA-29.64 Million
2018	-55.57%	0.00%	0.00x	1.36x	ILA-27.09 Million
2019	-80.31%	0.00%	0.00x	1.60x	ILA-30.14 Million
2020	-140.41%	0.00%	0.00x	2.15x	ILA-33.13 Million
2021	-41.34%	0.00%	0.00x	1.20x	ILA-34.95 Million
2022	-40.80%	0.00%	0.00x	1.50x	ILA-25.83 Million
2023	-458.40%	-1262.79%	0.08x	4.83x	ILA-61.94 Million
2024	-68.50%	-31.86%	0.74x	2.89x	ILA-10.57 Million

Industry Comparison

This section compares BioLine RX Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $112,362,556
Average return on equity (ROE) among peers: -121.34%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
BioLine RX Ltd (BLRX)	ILA19.53 Million	1.59%	1.04x	$9.10 Million
BioLight Life Sciences Ltd (BOLT)	$13.31 Million	0.00%	0.69x	$7.66 Million
Bonus Biogroup (BONS)	$84.43 Million	-106.69%	0.24x	$123.99 Million
Can Fite Biopharma Ltd (CANF)	$2.44 Million	-516.99%	2.35x	$5.56 Million
Clal Biotechnology Industries Ltd (CBI)	$808.20 Million	-3.45%	0.28x	$12.61 Million
Compugen (CGEN)	$19.58 Million	-61.30%	0.49x	$201.26 Million
DNA Biomed Solns (DNA)	$10.45 Million	0.00%	0.61x	$34.04 Million
Enlivex Therapeutics Ltd (ENLV)	$8.70 Million	-184.18%	0.22x	$458.60K
Evogene (EVGN)	$56.88 Million	-46.07%	0.26x	$4.88 Million
Kadimastem Ltd (KDST)	$7.28 Million	-173.39%	0.71x	$22.18 Million

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$9.10 Million

ILA3.39 Billion ILA

Market Cap Rank

#27266 Global

#392 in Israel

Share Price

ILA1.30

Change (1 day)

-7.14%

52-Week Range

ILA1.20 - ILA3.70

All Time High

ILA618.30